Age-preserving neuronal iSpheroids model aging and Alzheimer's disease
Directly converted neuronal spheroids from human fibroblasts kept donor epigenetic age and, from Alzheimer's donors, showed degeneration, amyloid-β and Tau changes in this abstract. [1]
Automatic summary · not editorially reviewed
The key findings
iSpheroids are made by direct conversion of primary fibroblasts without pluripotency and preserve donor-specific epigenetic age. [1]
Alzheimer iSpheroids spontaneously reproduced neuronal degeneration, amyloid-β accumulation, progressive Tau pathology and metabolic dysfunction. [1]
A multi-compound screen identified trametinib as a modulator of inflammatory and age-associated programs. [1]
The source at a glance
- Study type / format
- Preclinical cell-model study (abstract)
- Population / context
- Human neuronal spheroids derived from fibroblasts of young, unimpaired aged and sporadic Alzheimer's donors; also non-human primate fibroblasts.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- October 1, 2026
Fibroblast-derived iSpheroids keep donor epigenetic age
The authors describe iSpheroids as a scalable three-dimensional platform made by direct conversion of primary fibroblasts without a pluripotent step. Neurons from young, unimpaired aged and sporadic Alzheimer's donors were long-lived and electrophysiologically active, and donor-specific epigenetic age was preserved. Single-nucleus RNA sequencing found about 96% of cells had a neuronal identity across multiple neuronal states. The platform also allowed astrocytes and microglia to be added and could be generated from non-human primate fibroblasts.
Supporting source [1]
Alzheimer iSpheroids showed degeneration and pathology
According to the abstract, iSpheroids from sporadic Alzheimer's donors spontaneously reproduced neuronal degeneration, amyloid-β accumulation, progressive Tau pathology and metabolic dysfunction. Combined protein, metabolite and lipid profiling separated physiological aging from Alzheimer's disease and showed disease-associated metabolic remodeling. Oxaliplatin shifted Alzheimer iSpheroids toward oxidative metabolism, and a multi-compound screen identified trametinib as a modulator of inflammatory and age-associated programs. These are laboratory findings in a cell model, not evidence of benefit for people.
Supporting source [1]
Abstract-only scope of the iSpheroid report
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no sample sizes, donor numbers, follow-up periods or statistical uncertainty, so the strength and reproducibility of the findings cannot be judged here. The work is preclinical cell-model research; the drug screen results describe effects in iSpheroids and do not establish safety, dosing or benefit in humans.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No sample sizes, donor numbers, follow-up or statistical uncertainty are reported. Preclinical cell-model findings; drug effects in iSpheroids do not establish human safety, dosing or benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Alsolami S, Wang M, Sabedot TS, Singh U, Kirk B, Mitchell L, Hernandez M, Skvir N, Bowman C, Oiwa K, Agarwal R, Mahmoudi M, Cuoco MS, MacDonald E, Cranston S, Lucciola R, Boassa D, Herdy JR, Jones JR, Yoshikiyo K, Longevity Consortium, Mertens J, Martinez-Trujillo J, Jaremko L, Murphy GJ, Gage FH. · europepmc.org · October 1, 2026